{"analyses":[{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.409","pValueComment":"P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"Fisher Exact"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.371","pValueComment":"P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"Fisher Exact"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"Fisher Exact"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.007","pValueComment":"P-value is for Low Disease Activity - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"Fisher Exact"},{"ciNumSides":"TWO_SIDED","groupIds":["OG000","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.033","pValueComment":"P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"Fisher Exact"},{"ciNumSides":"TWO_SIDED","groupIds":["OG001","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.019","pValueComment":"P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"Fisher Exact"},{"ciNumSides":"TWO_SIDED","groupIds":["OG002","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"<0.001","pValueComment":"P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"Fisher Exact"},{"ciNumSides":"TWO_SIDED","groupIds":["OG003","OG004"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.001","pValueComment":"P-value is for Remission - Week 12. A priori p-value significance threshold: 2-sided ≤0.10.","statisticalMethod":"Fisher Exact"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"48"},{"groupId":"OG003","value":"40"},{"groupId":"OG004","value":"19"}]}],"title":"Low Disease Activity - Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"37"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"4"}]}],"title":"Remission - Week 12"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"31"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"46"},{"comment":"Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.","groupId":"OG004","value":"NA"}]}],"title":"Low Disease Activity - Week 24"},{"categories":[{"measurements":[{"comment":"Participants were not dosed with 1 mg LY3009104 after Week 12, therefore percentage was not calculated.","groupId":"OG000","value":"NA"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"33"},{"groupId":"OG003","value":"36"},{"comment":"Participants were not dosed with placebo after Week 12, therefore percentage was not calculated.","groupId":"OG004","value":"NA"}]}],"title":"Remission - Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"49"},{"groupId":"OG001","value":"52"},{"groupId":"OG002","value":"52"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"98"}],"units":"Participants"}],"description":"Disease Activity Score (DAS) modified to include 28-joint count (DAS28) consisted of composite score of following variables: tender joint count (TJC28), swollen joint count (SJC28), CRP \\[milligrams per liter (mg/L)\\], and Patient's Global Assessment of Disease Activity using VAS (patient's global VAS). Scores ranged from 1.0-9.4, where lower scores indicated less disease activity. DAS28 scores ≤3.2 are considered as low disease activity, and scores \\<2.6 are considered as remission. Participants who discontinue before analysis time points are treated as non-responders.","groups":[{"description":"1 mg LY3009104 administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG000","title":"1 mg LY3009104"},{"description":"2 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG001","title":"2 mg LY3009104"},{"description":"4 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG002","title":"4 mg LY3009104"},{"description":"8 mg LY3009104 administered orally QD for 24 weeks in Parts A and B.\n\nMTX was administered orally as background therapy.","id":"OG003","title":"8 mg LY3009104"},{"description":"Placebo administered orally QD for 12 weeks in Part A.\n\nMTX was administered orally as background therapy.","id":"OG004","title":"Placebo"}],"paramType":"NUMBER","populationDescription":"All randomized participants who received study drug in Parts A and B and had DAS28-CRP evaluated at analysis time points.","reportingStatus":"POSTED","timeFrame":"Baseline through Weeks 12 and 24","title":"Percentage of Participants Meeting Low Disease Activity and Remission Based on the 28 Diarthrodial Joint Count (DAS28) Baseline Through Weeks 12 and 24","type":"SECONDARY","unitOfMeasure":"percentage of participants"}